Grace Therapeutics, Inc. Deferred Costs, Current
Grace Therapeutics, Inc. (GRCE) had Deferred Costs, Current of $130.00 thousand as of 2020-06-30, per its 10-Q filed 2020-08-13.
Discontinued › Balance Sheet › Assets › Assets, Current
us-gaap:DeferredCostsCurrent · last filed 2021-06-22
- 2020-06-30: Deferred Costs, Current $130.00K.
- 2020-03-31: Deferred Costs, Current $121.00K.
- 2019-03-31: Deferred Costs, Current $134.00K.
| Period end | Deferred Costs, Current |
|---|---|
| 2020-06-30 | $130.00K 10-Q · filed 2020-08-13 |
| 2020-03-31 | $121.00K 10-K · filed 2021-06-22 |
| 2019-03-31 | $134.00K 10-K · filed 2020-06-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| PDS Biotechnology Corp (PDSB) | United States | $0.045B | |
| SCYNEXIS INC (SCYX) | United States | $0.045B | |
| Werewolf Therapeutics, Inc. (HOWL) | United States | $0.047B | |
| VERU INC. (VERU) | United States | $0.043B | -3.93 |
| Dogwood Therapeutics, Inc. (DWTX) | United States | $0.049B | |
| Lite Strategy, Inc. (LITS) | United States | $0.049B | |
| Elicio Therapeutics, Inc. (ELTX) | United States | $0.049B | |
| Kairos Pharma, LTD. (KAPA) | United States | $0.041B | |
| Incannex Healthcare Inc. (IXHL) | $0.040B | -22.32 | |
| Karyopharm Therapeutics Inc. (KPTI) | United States | $0.039B | -0.98 |